Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Rating) shares dropped 0.7% on Friday . The stock traded as low as C$2.91 and last traded at C$2.91. Approximately 300 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 1,411 shares. The stock had previously closed at C$2.93.
Analyst Ratings Changes
Separately, Raymond James raised their price target on shares of Eupraxia Pharmaceuticals from C$9.00 to C$11.00 in a report on Friday, February 24th.
Eupraxia Pharmaceuticals Price Performance
The business’s fifty day simple moving average is C$3.01 and its two-hundred day simple moving average is C$2.31.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis.
Featured Stories
- Get a free copy of the StockNews.com research report on Eupraxia Pharmaceuticals (EPRXF)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
